Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ethambutol + ofloxacin is a combination regimen consisting of two small molecule antibiotics used primarily in the treatment of tuberculosis (TB), especially in patients who cannot tolerate first-line agents due to liver injury or other contraindications. Ethambutol is a bacteriostatic agent that inhibits arabinosyl transferases involved in mycobacterial cell wall synthesis, while ofloxacin is a fluoroquinolone that inhibits bacterial DNA gyrase and topoisomerase IV, disrupting DNA replication and transcription. This combination has been shown to be effective as part of multi-drug regimens for TB, including cases with hepatic impairment or drug resistance[2][8]. Both drugs are administered orally.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ethambutol + ofloxacin.